Abivax's Obefazimod: Europe's Top-Performing Stock

Abivax, a French biotech company, has seen its market value soar over a thousand percent this year, making it Europes top-performing stock. The surge began after positive results for its experimental drug, obefazimod, which treats ulcerative colitis. Investors are eagerly awaiting further results, expected in the second quarter of 2026, which could allow Abivax to seek regulatory approval. Analysts predict peak sales of around seven billion dollars, capturing a significant share of the market for both ulcerative colitis and Crohns disease. Abivax plans to file for US regulatory approval by the end of 2026, with a target launch in the third quarter of 2027. Investors see potential for acquisition, with major financial institutions like Goldman Sachs adding Abivax to their list of hedge fund favorites.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.